The role of xenoestrogenic compounds in the development of breast cancer

Trends in Pharmacological Sciences

Volumn 27, Issue 8, 2006, Pages 447-454

  Safe, Stephen ^a,b   Papineni, Sabitha ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,1 DICHLORO 2,2 BIS(4 CHLOROPHENYL)ETHYLENE; 4 HYDROXYTAMOXIFEN; 4,4' ISOPROPYLIDENEDIPHENOL; ANTIESTROGEN; CHLORDECONE; ESTROGEN; ESTROGEN DERIVATIVE; ESTROGEN RECEPTOR ALPHA; FLAVONOL DERIVATIVE; ISOFLAVONE DERIVATIVE; LIGNAN DERIVATIVE; NARINGENIN; NONYLPHENOL; ORGANOCHLORINE PESTICIDE; PHYTOESTROGEN; POLYCHLORINATED BIPHENYL; RALOXIFENE; RESVERATROL; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; UNCLASSIFIED DRUG; XENOESTROGEN;

BREAST CANCER; BREAST CARCINOGENESIS; BREAST DEVELOPMENT; CANCER INCIDENCE; CANCER RISK; DRUG EFFECT; HUMAN; MAMMARY GLAND; NONHUMAN; PRIORITY JOURNAL; REVIEW;

BREAST NEOPLASMS; ENVIRONMENTAL POLLUTANTS; FEMALE; HUMANS; MOLECULAR STRUCTURE; PHYTOESTROGENS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TIME FACTORS;

EID: 33745890588     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2006.06.006     Document Type: Review

References (67)

1. Althuis M.D., et al. Global trends in breast cancer incidence and mortality 1973-1997. Int. J. Epidemiol. 34 (2005) 405-412
2. Hilakivi-Clarke L. Estrogens, BRCA1, and breast cancer. Cancer Res. 60 (2000) 4993-5001
3. Bernstein L. Epidemiology of endocrine-related risk factors for breast cancer. J. Mammary Gland Biol. Neoplasia 7 (2002) 3-15
4. Bolton J.L. Quinoids, quinoid radicals, and phenoxyl radicals formed from estrogens and antiestrogens. Toxicology 177 (2002) 55-65
5. Russo J., and Russo I.H. Role of differentiation in the pathogenesis and prevention of breast cancer. Endocr. Relat. Cancer 4 (1997) 7-21
6. Russo J., et al. Breast differentiation and its implication in cancer prevention. Clin. Cancer Res. 11 (2005) 931s-936s
7. Rossouw J.E., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J. Am. Med. Assoc. 288 (2002) 321-333
8. Cogliano V., et al. Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol. 6 (2005) 552-553
9. Trichopoulos D. Hypothesis: does breast cancer originate in utero?. Lancet 335 (1990) 939-940
10. Cerhan J.R., et al. Twinship and risk of postmenopausal breast cancer. J. Natl. Cancer Inst. 92 (2000) 261-265
11. Palmer J.R., et al. Risk of breast cancer in women exposed to diethylstilbestrol in utero: prelimiinary results (United States). Cancer Causes Control 13 (2002) 753-758
12. Strohsnitter W.C., et al. Breast cancer incidence in women prenatally exposed to maternal cigarette smoke. Epidemiology 16 (2005) 342-345
13. Egan K.M., et al. Active and passive smoking in breast cancer: prospective results from the Nurses' Health Study. Epidemiology 13 (2002) 138-145
14. John E.M., and Kelsey J.L. Radiation and other environmental exposures and breast cancer. Epidemiol. Rev. 15 (1993) 157-162
15. Baron J.A., et al. The antiestrogenic effect of cigarette smoking in women. Am. J. Obstet. Gynecol. 162 (1990) 502-514
16. Shoff S.M., et al. Early-life physical activity and postmenopausal breast cancer: effect of body size and weight change. Cancer Epidemiol. Biomarkers Prev. 9 (2000) 591-595
17. Van Hoften C., et al. Long-term oral contraceptive use increases breast cancer risk in women over 55 years of age: the DOM cohort. Int. J. Cancer 87 (2000) 591-594
18. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362 (2003) 419-427
19. Falck F., et al. Pesticides and polychlorinated biphenyl residues in human breast lipids and their relation to breast cancer. Arch. Environ. Health 47 (1992) 143-146
20. Wolff M.S., et al. Blood levels of organochlorine residues and risk of breast cancer. J. Natl. Cancer Inst. 85 (1993) 648-652
21. Davis D.L., et al. Medical hypothesis: xenoestrogens as preventable causes of breast cancer. Environ. Health Perspect. 101 (1993) 372-377
22. Hunter D.J., and Kelsey K.T. Pesticide residues and breast cancer: the harvest of a silent spring. J. Natl. Cancer Inst. 85 (1993) 598-599
23. Safe S. Environmental and dietary estrogens and human health - is there a problem?. Environ. Health Perspect. 103 (1995) 346-351
24. Silinskas K.C., and Okey A.B. Protection by 1,1,1-trichloro-2,2-bis(p-chlorophenyl)ethane (DDT) against mammary tumors and leukemia during prolonged feeding of 7,12-dimethylbenz(a)anthracene to female rats. J. Natl. Cancer Inst. 55 (1975) 653-657
25. Mayes B.A., et al. Comparative carcinogenicity in Sprague-Dawley rats of the polychlorinated biphenyl mixtures Aroclors 1016, 1242, 1254, and 1260. Toxicol. Sci. 41 (1998) 62-76
26. Lopez-Cervantes M., et al. Dichlorodiphenyldichloroethane burden and breast cancer risk: a meta-analysis of the epidemiologic evidence. Environ. Health Perspect. 112 (2004) 207-214
27. Safe S. Clinical correlates of environmental endocrine disruptors. Trends Endocrinol. Metab. 16 (2005) 139-144
28. Gammon M.D., et al. Environmental toxins and breast cancer on Long Island. II. Organochlorine compound levels in blood. Cancer Epidemiol. Biomarkers Prev. 11 (2002) 686-697
29. Grace P.B., et al. Phytoestrogen concentrations in serum and spot urine as biomarkers for dietary phytoestrogen intake and their relation to breast cancer risk in European Prospective Investigation of Cancer and Nutrition-Norfolk. Cancer Epidemiol. Biomarkers Prev. 13 (2004) 698-708
30. Safe S., et al. Problems for risk assessment of endocrine-active estrogenic compounds. Environ. Health Perspect. 110 (2002) 925-929
31. Adlercreutz H. Phytoestrogens and breast cancer. J. Steroid Biochem. Mol. Biol. 83 (2002) 113-118
32. Dai Q., et al. Population-based case-control study of soyfood intake and breast cancer risk in Shanghai. Br. J. Cancer 85 (2001) 372-378
33. Wu A.H., et al. Adolescent and adult soy intake and risk of breast cancer in Asian-Americans. Carcinogenesis 23 (2002) 1491-1496
34. Wu A.H., et al. Plasma isoflavone levels versus self-reported soy isoflavone levels in Asian-American women in Los Angeles County. Carcinogenesis 25 (2004) 77-81
35. dos Santos Silva I., et al. Phyto-oestrogen intake and breast cancer risk in South Asian women in England: findings from a population-based case-control study. Cancer Causes Control 15 (2004) 805-818
36. Keinan-Boker L., et al. Dietary phytoestrogens and breast cancer risk. Am. J. Clin. Nutr. 79 (2004) 282-288
37. Kilkkinen A., et al. Serum enterolactone concentration is not associated with breast cancer risk in a nested case-control study. Int. J. Cancer 108 (2004) 277-280
38. McCann S.E., et al. Dietary lignan intakes and risk of pre- and postmenopausal breast cancer. Int. J. Cancer 111 (2004) 440-443
39. Stuedal A., et al. Plasma levels of enterolactone and percentage mammographic density among postmenopausal women. Cancer Epidemiol. Biomarkers Prev. 14 (2005) 2154-2159
40. Adebamowo C.A., et al. Dietary flavonols and flavonol-rich foods intake and the risk of breast cancer. Int. J. Cancer 114 (2005) 628-633
41. Krishnan V., et al. Mechanism of action of estrogens and selective estrogen receptor modulators. Vitam. Horm. 60 (2001) 123-147
42. Jordan V.C. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents. J. Med. Chem. 46 (2003) 1081-1111
43. Jordan V.C. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions. J. Med. Chem. 46 (2003) 883-908
44. Katzenellenbogen J.A., et al. Tripartite steroid hormone receptor pharmacology - interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. Mol. Endocrinol. 10 (1996) 119-131
45. Smith C.L., and O'Malley B.W. Coregulator function: a key to understanding tissue specificity of selected receptor modulators. Endocr. Rev. 25 (2004) 45-71
46. Bernstein L., et al. Tamoxifen therapy for breast cancer and endometrial cancer risk. J. Natl. Cancer Inst. 91 (1999) 1654-1662
47. MacGregor J.I., and Jordan V.C. Basic guide to the mechanisms of antiestrogen action. Pharmacol. Rev. 50 (1998) 151-196
48. Tzukerman M.T., et al. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol. Endocrinol. 8 (1994) 21-30
49. McDonnell D.P., et al. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol. Endocrinol. 9 (1995) 659-669
50. Yoon K., et al. Ligand structure-dependent differences in activation of estrogen receptor α in human HepG2 liver and U2 osteogenic cancer cell lines. Mol. Cell. Endocrinol. 162 (2000) 211-220
51. Yoon K., et al. Differential activation of wild-type and variant forms of estrogen receptor α by synthetic and natural estrogenic compounds using a promoter containing three tandem estrogen-responsive elements. J. Steroid Biochem. Mol. Biol. 78 (2001) 25-32
52. Gould J.C., et al. Bisphenol A interacts with the estrogen receptor α in a distinct manner from estradiol. Mol. Cell. Endocrinol. 142 (1998) 203-214
53. Gaido K.W., et al. Differential interaction of the methoxychlor metabolite HPTE with estrogen receptors α and β. Endocrinology 140 (1999) 5746-5753
54. Gaido K.W., et al. Interaction of methoxychlor and related compounds with estrogen receptor α and β, and androgen receptor: structure-activity studies. Mol. Pharmacol. 58 (2000) 852-858
55. Jordan V.C., et al. Molecular classification of estrogens. Cancer Res. 61 (2001) 6619-6623
56. Nesaretnam K., et al. 3,4,3′,4′-Tetrachlorobiphenyl acts as an estrogen in vitro and in vivo. Mol. Endocrinol. 10 (1996) 923-936
57. An J., et al. Estrogen receptor β-selective transcriptional activity and recruitment of coregulators by phytoestrogens. J. Biol. Chem. 276 (2001) 17808-17814
58. Barkhem T., et al. Differential response of estrogen receptor α and estrogen receptor β to partial estrogen agonists/antagonists. Mol. Pharmacol. 54 (1998) 105-112
59. Mueller S.O., et al. Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor α (ERα) and ERβ in human cells. Toxicol. Sci. 80 (2004) 14-25
60. Hall J.M., et al. Allosteric regulation of estrogen receptor structure, function, and coactivator recruitment by different estrogen response elements. Mol. Endocrinol. 16 (2002) 469-486
61. Safe S., and Kim K. Nuclear receptor-mediated transactivation through interaction with Sp proteins. Prog. Nucleic Acid Res. Mol. Biol. 77 (2004) 1-36
62. Li X., et al. Activation of kinase pathways in MCF-7 cells by 17β-estradiol and structurally-diverse estrogenic compounds. J. Steroid Biochem. Mol. Biol. 98 (2006) 122-132
63. Hunt P.A., et al. Bisphenol A exposure causes meiotic aneuploidy in the female mouse. Curr. Biol. 13 (2003) 546-553
64. Schonfelder G., et al. In utero exposure to low doses of bisphenol A lead to long-term deleterious effects in the vagina. Neoplasia 4 (2002) 98-102
65. Tabb M.M., and Blumberg B. New modes of action for endocrine-disrupting chemicals. Mol. Endocrinol. 20 (2006) 475-482
66. Vivacqua A., et al. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17β-estradiol and hydroxytamoxifen in endometrial cancer cells. Mol. Endocrinol. 20 (2006) 631-646
67. Newbold R.R., et al. Developmental exposure to estrogenic compounds and obesity. Birth Defects Res. A Clin. Mol. Teratol. 73 (2005) 478-480